Skip to content

Tarsus Pharmaceuticals, Inc. TARS Preferred Stock, Shares Outstanding

Preferred Stock, Shares Outstanding at other companies

General Dynamics logo
General DynamicsGD
0
Apollo Global Management logo
Apollo Global ManagementAPO
28.7M0.0%
Mondelez International logo
Mondelez InternationalMDLZ
0
Bank of America logo
Bank of AmericaBAC
4M+4.8%
L3Harris Technologies logo
L3Harris TechnologiesLHX
0
Phillips 66 logo
Phillips 66PSX
0

Other financials

Income statement

See full
Revenue$162.1M+107%
Gross profit$152.7M+109%
Operating income-$6.1M+76.7%
Net income-$7.0M+72.3%
EPS (diluted)-$0.16+75.0%

Balance sheet

See full
Cash & equivalents$104.2M-41.6%
Total debt$88.7M+22.5%
Total equity$349.0M+1.9%
Total assets$581.1M+16.1%

Cash flow

See full
Operating cash flow-$24.7M-19.4%
CapEx$5.8M+886%
Free cash flow-$30.5M-43.4%

Valuation

See full
Market cap$2.85B+41.1%
Enterprise value$2.83B+47.8%
P/S5.3×-3.3×

Profitability

See full
Gross margin42.7%
Operating margin-9.5%-4.2pp
Net margin-9%-4.0pp
FCF margin-28%-12.6pp

Returns & leverage

See full
Return on equity-14%-5.2pp
Debt / equity0.3×0.0×
Current ratio3.7×-1.8×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesOutstanding.

The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tarsus Pharmaceuticals, Inc.'s preferred stock, shares outstanding.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tarsus Pharmaceuticals, Inc.'s preferred stock, shares outstanding?
Tarsus Pharmaceuticals, Inc. (TARS) reported preferred stock, shares outstanding of $0 in Q1 2026.